An observational study in Leukemia, Myeloid, Chronic-Phase, sponsored by Novartis Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-02.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Leukemia, Myeloid, Chronic-Phase by Novartis — 2 open to participants now, 3 under way, none of them phase 3. Leukemia, Myeloid, Chronic-Phase · Novartis.
Among the 14 studies in Leukemia, Myeloid, Chronic-Phase by Novartis, this one is the only one that started in 2024, is one of 4 observational ones, and was the 13th registered.
439 studies on the registry are indexed under Leukemia, Myeloid, Chronic-Phase; 27 are open to participants now.
Browse Leukemia, Myeloid, Chronic-Phase studies →2 of the 14 studies in Leukemia, Myeloid, Chronic-Phase by Novartis are open now, in 1 country. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 18–100
Novartis Pharmaceuticals
Ages 21–90
By country, each count listing its studies:
Of the 21 Leukemia, Myeloid, Chronic-Phase studies recruiting now, 14 (67%) set no upper age limit and 5 (24%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 3 · Phase 4 1
First in 2000; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,480 is above the median of 100 across 43 observational studies indexed under Leukemia, Myeloid, Chronic-Phase.
Median enrollment 45 across the 6 interventional studies, 700 across the 4 observational. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,723 studies on the registry; 222 are open to participants now.
Of its 587 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
1 of the studies in Leukemia, Myeloid, Chronic-Phase by Novartis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07454850Novartis PharmaceuticalsA Study of Patient Characteristics, Co-Morbidities, and Treatment Patterns in Chronic Myeloid Leukemia Patients in Kuwait | 2027-07-02 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in Leukemia, Myeloid, Chronic-Phase by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This was a retrospective observational study to examine treatment patterns, molecular testing patterns, treatment response, and clinical outcomes among patients initiating first-line (1L) tyrosine kinase inhibitor (TKI) treatment for CML-CP in The United States (US) Oncology Network practices.
Patients who initiated 1L therapy between 01 January 2016 and 31 December 2022 were eligible for inclusion in the study. Study-eligible patients were followed longitudinally post-index until death (if the patient had documentation of death during the study observation period) or last available patient record that occurred on or before the end of the study observation period. The study observation period was from 01 January 2016 to 30 November 2023. The index date was defined as the start date of 1L therapy for CML-CP.
This was a retrospective, noninterventional cohort study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Patients with a diagnosis of CML-CP who initiated 1L TKI treatment in The US Oncology Network practices between 01 January 2016 and 31 December 2022.
Time From Initial CML Diagnosis to Initiation of 1L TKI Treatment
Time frame: Baseline
Number of Patients who Received a Stem Cell Transplant (SCT)
Time frame: Up to approximately 7 years
Number of Patients by Type of 1L and Second-line (2L) TKI Treatment
Time frame: Up to approximately 7 years
Number of Patients by Initial Dose of Each TKI in 1L and 2L Treatment
Time frame: Up to approximately 7 years
Number of Patients by Treatment Sequence From 1L TKI to 2L TKI Treatment
Time frame: Up to approximately 7 years
Number of Patients by Dose Modification of 1L and 2L TKI Treatment
Dose modifications included dose escalation, reduction, or hold.
Time frame: Up to approximately 7 years
Number of Patients by Reason for Dose Modification of 1L and 2L TKI Treatment
Dose modifications included dose escalation, reduction, or hold.
Time frame: Up to approximately 7 years
Number of Patients who Discontinued 1L and 2L TKI Treatment
Time frame: Up to approximately 7 years
Number of Patients by Reason for Discontinuing 1L and 2L TKI Treatment
Time frame: Up to approximately 7 years
Number of Patients by Clinical Events of Interest During 1L and 2L TKI Treatment
Clinical events of interest included: * Alopecia * Anemia * Arthralgia/Myalgia * Diarrhea * Elevated liver enzyme * Elevated serum creatinine * Fatigue * Febrile neutropenia * Infection secondary to neutropenia * Interstitial lung disease-like events * Leukopenia * Nausea * Neutropenia * Pain * Prolongation of QT interval * Thrombocytopenia * Venous embolism (including pulmonary embolism and/or deep vein thrombosis) * Vomiting
Time frame: Up to approximately 7 years
Number of Patients by Best Overall Molecular Response (MR) Achieved During 1L and 2L TKI Treatment
MR was based on BCR::ABL (International Scale \[IS\]) qPCR testing results. Molecular response was categorized as: * MR 2: if BCR::ABL (IS) \>0.1% - ≤ 1% * Major MR (MMR)/MR 3: if BCR::ABL(IS) \>0.01% - ≤0.1% * MR 4: if BCR::ABL1 (IS) \>0.0032% -≤0.01% * MR 4.5: if BCR::ABL (IS) ≤0.0032% * Not documented
Time frame: Up to approximately 7 years
Number of Patients by Best Overall MR Achieved Within 12 Months of Initiating 1L and 2L TKI Treatment
MR was based on BCR::ABL (IS) qPCR testing results. Molecular response was categorized as: * MR 2: if BCR::ABL (IS) \>0.1% - ≤ 1% * Major MR (MMR)/MR 3: if BCR::ABL(IS) \>0.01% - ≤0.1% * MR 4: if BCR::ABL1 (IS) \>0.0032% -≤0.01% * MR 4.5: if BCR::ABL (IS) ≤0.0032% * Not documented
Time frame: From Baseline up to 12 months
Number of Patients by MR Achieved After Initiating 1L and 2L TKI Treatment
MR was based on BCR::ABL (IS) qPCR testing results. Molecular response was categorized as: * MR 2: if BCR::ABL (IS) \>0.1% - ≤ 1% * Major MR (MMR)/MR 3: if BCR::ABL(IS) \>0.01% - ≤0.1% * MR 4: if BCR::ABL1 (IS) \>0.0032% -≤0.01% * MR 4.5: if BCR::ABL (IS) ≤0.0032% * Not documented
Time frame: 6, 12, 18, and 24 months
Number of Patients who Achieved a BCR::ABL (IS) Result ≤10% Within 6 Months of Initiating 1L and 2L TKI Treatment
Time frame: From Baseline up to 6 months
Number of Patients who Achieved or Sustained a BCR::ABL (IS) Result <1% Between 6 and 12 Months After Initiating 1L and 2L TKI Treatment
Time frame: From Month 6 to Month 12
Number of Patients who Achieved or Sustained a BCR::ABL (IS) Result ≤0.1% Between 13 and 24 Months After Initiating 1L and 2L TKI Treatment
Time frame: From Month 13 to Month 24
Number of Patients who Achieved or Sustained a BCR::ABL (IS) Result ≤0.1% After 24 Months Following Initiating 1L and 2L TKI Treatment
Time frame: From Month 24 to end of study, up to approximately 6 years
Number of Patients who Achieved Complete Hematologic Response (CHR) During 1L and 2L TKI Treatment
CHR was observed when white blood cells, hemoglobin, and platelet counts were all within each respective normal lab range.
Time frame: Up to approximately 7 years
Number of Patients who Achieved CHR Within 12 Months of Initiating 1L and 2L TKI Treatment
CHR was observed when white blood cells, hemoglobin, and platelet counts were all within each respective normal lab range.
Time frame: From Baseline up to 12 months
Number of Patients who Achieved Complete Cytogenetic Response (CCyR) During 1L and 2L TKI Treatment
Cytogenetic response was based on the Philadelphia chromosome results. CCyR was defined as having no Philadelphia chromosome-positive metaphases.
Time frame: Up to approximately 7 years
Number of Patients who Achieved CCyR Within 12 Months of Initiating 1L and 2L TKI Treatment
Cytogenetic response was based on the Philadelphia chromosome results. CCyR was defined as having no Philadelphia chromosome-positive metaphases.
Time frame: From Baseline up to 12 months
Duration of Therapy (DOT) for 1L TKI Treatment
DOT was defined as the interval between the start date of the 1L therapy (index date) and the end date of 1L therapy, including any treatment interruptions or other breaks.
Time frame: Up to approximately 7 years
DOT for 2L TKI Treatment
DOT was defined as the interval between the start date of the 2L therapy and the end date of 2L therapy, including any treatment interruptions or other breaks.
Time frame: Up to approximately 7 years
Progression-free Survival (PFS) for 1L TKI Treatment
PFS was defined as physician-documented progression, loss of MR2, BCR::ABL (IS) ≤1%, or an increase in BCR::ABL1 transcript to \>1%, or a 1-log increase in BCR::ABL1 transcript levels with loss of MMR.
Time frame: Up to approximately 7 years
PFS for 2L TKI Treatment
PFS was defined as physician-documented progression, loss of MR2, BCR::ABL (IS) ≤1%, or an increase in BCR::ABL1 transcript to \>1%, or a 1-log increase in BCR::ABL1 transcript levels with loss of MMR.
Time frame: Up to approximately 7 years
Overall Survival (OS) for 1L TKI Treatment
OS was defined as the interval between the start date of 1L therapy (index date) and the date of death (any cause).
Time frame: Up to approximately 7 years
Overall Survival (OS) for 2L TKI Treatment
OS was defined as the interval between the start date of 2L therapy and the date of death (any cause).
Time frame: Up to approximately 7 years
Treatment-free Interval (TFI)
TFI was defined as the interval between the discontinuation date of 1L therapy and the start date of 2L therapy or date of death.
Time frame: Up to approximately 7 years
Number of Patients With BCR::ABL Testing (per National Comprehensive Cancer Network (NCCN) Guidelines) at Diagnosis
Time frame: Baseline
Number of Patients With BCR::ABL Testing (per NCCN Guidelines) in 3-Month Intervals After Initiation of 1L and 2L TKI Treatment Until BCR::ABL1 ≤1% was Achieved
Time frame: Up to approximately 7 years
After Initiation of 1L and 2L TKI Treatment, Number of Patients With BCR::ABL Testing (per NCCN Guidelines) in 3-Month Intervals Within 2 Years After BCR::ABL1 ≤1% was Achieved
Time frame: 2 years
After Initiation of 1L and 2L TKI Treatment, Number of Patients With BCR::ABL Testing (per NCCN Guidelines) Between 1 and 3 Months Following 2 Years After BCR::ABL1 ≤1% was Achieved
Time frame: Up to approximately 5 years
Number of BCR::ABL Tests (per NCCN Guidelines) After Initiation of 1L and 2L TKI Treatment Until BCR::ABL1 ≤1% was Achieved
Time frame: Up to approximately 7 years
Following Initiation of 1L and 2L TKI Treatment, Number of BCR::ABL Tests (per NCCN Guidelines) Within 2 Years After Achieving BCR::ABL1 ≤1%
Time frame: 2 years
Following Initiation of 1L and 2L TKI Treatment, Number of BCR::ABL Tests (per NCCN Guidelines) Performed After 2 Years of Achieving BCR::ABL1 ≤1%
Time frame: Up to approximately 5 years
Number of Patients With BCR::ABL Testing (per European LeukemiaNet (ELN) Guidelines) at Diagnosis
Time frame: Baseline
Number of Patients With BCR::ABL Testing (per ELN Guidelines) in 3-Month Intervals After Initiation of 1L and 2L TKI Treatment Until BCR::ABL1 ≤0.1% was Achieved
Time frame: Up to approximately 7 years
Number of Patients With BCR::ABL Testing (per ELN Guidelines) Tested in 3-Month Intervals After Initiation of 1L Until BCR::ABL1 ≤0.1% was Achieved and Tested Between 2 to 6 Months Until CCyR was Achieved
Time frame: 5 months
Number of Patients With BCR::ABL Testing (per ELN Guidelines) Tested in 3-Month Intervals After Initiation of 2L Until BCR::ABL1 ≤0.1% was Achieved and Tested Between 2 to 6 Months Until CCyR was Achieved
Time frame: 5 months
Number of Patients With BCR::ABL Testing (per ELN Guidelines) Tested in 3-Month Intervals After Initiation of 1L Until BCR::ABL1 ≤0.1% was Achieved and Tested Every 12 Months Until CCyR was Achieved
Time frame: Up to approximately 7 years
Number of Patients With BCR::ABL Testing (per ELN Guidelines) Tested in 3-Month Intervals After Initiation of 2L Until BCR::ABL1 ≤0.1% was Achieved and Tested Every 12 Months Until CCyR was Achieved
Time frame: Up to approximately 7 years
Number of BCR::ABL Tests (per ELN Guidelines) After Initiation of 1L and 2L TKI Treatment Until BCR::ABL1 ≤0.1% was Achieved
Time frame: Up to approximately 7 years
Number of BCR::ABL Tests (per ELN Guidelines) After Initiation of 1L and 2L TKI Treatment Until CCyR was Achieved
Time frame: Up to approximately 7 years
Number of Molecular Testing by Year Following Initiation of 1L TKI Treatment During Which the T315I Mutation was Identified
Time frame: Up to approximately 7 years
Number of Patients With T3151 Mutation Testing During 1L and 2L TKI Treatment
Time frame: Up to approximately 7 years
Ran from Feb 2024 to primary completion in Jan 2025, 11 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Leukemia, Myeloid, Chronic-Phase →